View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPMD Device Solutions 향후 성장Future 기준 점검 2/6PMD Device Solutions의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Biotechs 이익 성장22.7%매출 성장률50.9%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트03 Dec 2024최근 향후 성장 업데이트공시 • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.모든 업데이트 보기Recent updatesNew Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr115m). Market cap is less than US$10m (€5.17m market cap, or US$5.55m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr40m revenue, or US$3.7m).공시 • Oct 29PMD Device Solutions AB Approves Board ChangesPMD Device Solutions AB at its EGM held on October 29, 2024 approved that the board of directors shall consist of Martin Roos (new election) and Sten Dahlborg (new election). It was further resolved to elect Sten Dahlborg as chairman of the board. Peter Donnelly therefore resigns as member of the board as well as chairman. Martin Roos: Martin Roos is an INSEAD certified board director (IDP) with board and executive experience from telecom, tech and biotech. He currently serves as the chairman for Seamless Distribution Systems and is a board member of Nexam Chemicals and Redsense Medical (listed on NGM Nordic SME, Nasdaq First North and Spotlight respectively). He also serves on the board of startups such as Lignin Industries. Martin has previously served on the board operating committee of WOM in Chile and was the CEO for Cable and Wireless Caribbean and Altice in the Dominican Republic (integrating Orange with Tricom), in addition to senior leadership positions with Ericsson. During his tenure at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago. Martin holds an MSc in Economics from Stockholm School of Economics, a MSc in Chemical Engineering from The Royal Institute of Technology in Stockholm. Sten Dahlborg: Sten Dahlborg is an accomplished executive with over 20 years of experience in the Medtech industry and investment management. He has served as the chairman and managing director of several companies, including Ascilion and CGI Healthcare, where he successfully led strategic exits and business development initiatives. As a business advisor and board member for various medical technology firms, he has played a pivotal role in fostering innovation and commercialization within the sector. Currently, Sten is the CEO of CGI Ventures AB, advising new businesses on strategic growth and mergers and acquisitions, and serves as a co-owner of CITRUS MÉXICO. His expertise in adaptive leadership and investment management, coupled with a strong focus on commercial success, positions him as a leader in driving advancements in healthcare technology.공시 • Oct 11PMD Device Solutions Announces Board and Executive ChangesPMD Device Solutions announced that its largest founding shareholder, Miman Ventures AB, has requested the Board of PMDS to convene an Extraordinary General Meeting (EGM) to appoint new Non-Executive Directors. This request follows recent management changes and forms part of a broader transition in the company's governance and operational structure. The company has recently seen the resignation of Magnus Christensen, Christer Ahlberg, and Anne Dorney. Anne, who has been an Executive Director, will also be retiring with immediate effect from her role as Chief Compliance Officer. In light of these departures, PMDS will actively engage in appointing new individuals who will support the company's continued growth.Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr12.4m (up 2.6% from 2Q 2023). Net loss: kr11.7m (loss widened 85% from 2Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.공시 • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.New Risk • Jun 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr106m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr37m revenue, or US$3.5m). Market cap is less than US$100m (€12.9m market cap, or US$13.9m).공시 • Apr 09PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ).PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ) on April 9, 2024. On March 22, 2024, the Board of Directors of Coala Life filed for bankruptcy. The transaction will be closed no later than April 10th, 2024.공시 • Mar 01+ 4 more updatesPMD Device Solutions AB to Report Nine Months, 2024 Results on Nov 22, 2024PMD Device Solutions AB announced that they will report nine months, 2024 results on Nov 22, 2024공시 • Jan 24PMD Device Solutions AB to Report Fiscal Year 2023 Results on Feb 29, 2024PMD Device Solutions AB announced that they will report fiscal year 2023 results on Feb 29, 2024이익 및 매출 성장 예측DB:8T00 - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2027203N/AN/AN/A112/31/2026124N/A-75112/31/202575N/A-10N/A112/31/202442N/A-17-1419/30/202439-48-35-33N/A6/30/202440-44-15-14N/A3/31/202437-39-18-16N/A12/31/202338-39-22-18N/A3/31/202318-3615N/A애널리스트 향후 성장 전망수입 대 저축률: 8T00 의 예상 수익 증가율이 절약률(1%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: 8T00 의 수익이 German 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: 8T00 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: 8T00 의 수익(연간 50.9%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 8T00 의 수익(연간 50.9%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 8T00의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/01/16 19:14종가2024/12/23 00:00수익2024/09/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PMD Device Solutions AB는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Johan UnnerusRedeye
공시 • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.
New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr115m). Market cap is less than US$10m (€5.17m market cap, or US$5.55m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr40m revenue, or US$3.7m).
공시 • Oct 29PMD Device Solutions AB Approves Board ChangesPMD Device Solutions AB at its EGM held on October 29, 2024 approved that the board of directors shall consist of Martin Roos (new election) and Sten Dahlborg (new election). It was further resolved to elect Sten Dahlborg as chairman of the board. Peter Donnelly therefore resigns as member of the board as well as chairman. Martin Roos: Martin Roos is an INSEAD certified board director (IDP) with board and executive experience from telecom, tech and biotech. He currently serves as the chairman for Seamless Distribution Systems and is a board member of Nexam Chemicals and Redsense Medical (listed on NGM Nordic SME, Nasdaq First North and Spotlight respectively). He also serves on the board of startups such as Lignin Industries. Martin has previously served on the board operating committee of WOM in Chile and was the CEO for Cable and Wireless Caribbean and Altice in the Dominican Republic (integrating Orange with Tricom), in addition to senior leadership positions with Ericsson. During his tenure at Cable and Wireless, Martin also served on the Board of Directors of TSTT in Trinidad and Tobago. Martin holds an MSc in Economics from Stockholm School of Economics, a MSc in Chemical Engineering from The Royal Institute of Technology in Stockholm. Sten Dahlborg: Sten Dahlborg is an accomplished executive with over 20 years of experience in the Medtech industry and investment management. He has served as the chairman and managing director of several companies, including Ascilion and CGI Healthcare, where he successfully led strategic exits and business development initiatives. As a business advisor and board member for various medical technology firms, he has played a pivotal role in fostering innovation and commercialization within the sector. Currently, Sten is the CEO of CGI Ventures AB, advising new businesses on strategic growth and mergers and acquisitions, and serves as a co-owner of CITRUS MÉXICO. His expertise in adaptive leadership and investment management, coupled with a strong focus on commercial success, positions him as a leader in driving advancements in healthcare technology.
공시 • Oct 11PMD Device Solutions Announces Board and Executive ChangesPMD Device Solutions announced that its largest founding shareholder, Miman Ventures AB, has requested the Board of PMDS to convene an Extraordinary General Meeting (EGM) to appoint new Non-Executive Directors. This request follows recent management changes and forms part of a broader transition in the company's governance and operational structure. The company has recently seen the resignation of Magnus Christensen, Christer Ahlberg, and Anne Dorney. Anne, who has been an Executive Director, will also be retiring with immediate effect from her role as Chief Compliance Officer. In light of these departures, PMDS will actively engage in appointing new individuals who will support the company's continued growth.
Reported Earnings • Aug 23Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr12.4m (up 2.6% from 2Q 2023). Net loss: kr11.7m (loss widened 85% from 2Q 2023). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe.
공시 • Jun 26PMD Device Solutions AB Revises Earnings Guidance for the Year 2026PMD Device Solutions AB revised earnings guidance for the year 2026. The company revised its annual recurring revenue (ARR) target from SEK 100 million to SEK 260 million by yearend 2026. The increase is driven by the current strong business activity in the UK and the acquisition and subsequent restructuring of the US remote patient monitoring company. PMDS initially forecasted SEK 100 million of annual recurring revenue as part of its listing in January 2024.
New Risk • Jun 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr18m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr106m). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (kr37m revenue, or US$3.5m). Market cap is less than US$100m (€12.9m market cap, or US$13.9m).
공시 • Apr 09PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ).PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB (publ) on April 9, 2024. On March 22, 2024, the Board of Directors of Coala Life filed for bankruptcy. The transaction will be closed no later than April 10th, 2024.
공시 • Mar 01+ 4 more updatesPMD Device Solutions AB to Report Nine Months, 2024 Results on Nov 22, 2024PMD Device Solutions AB announced that they will report nine months, 2024 results on Nov 22, 2024
공시 • Jan 24PMD Device Solutions AB to Report Fiscal Year 2023 Results on Feb 29, 2024PMD Device Solutions AB announced that they will report fiscal year 2023 results on Feb 29, 2024